Adults aged 18 or older with a history of atopic dermatitis (AD) for at least 12 months, may qualify to participate. Individuals must have moderate to severe disease involving 10% or more body surface area. Documentation of inadequate response or intolerance to topical corticosteroids (TCS) within 6 months prior to study entry, is also required.
Participants will receive investigational oral medication (active study drug) or placebo, in tablet form. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 21 weeks and involve about 8 visits to the study centre.
If interested, please contact our Research Coordinator at 416-633-0001 x 4 or e-mail [email protected].
